Dr. Peters guided the early preclinical and clinical development of AKB-9778 while at Akebia and Aerpio, and currently leads scientific discovery and translational development for Aerpio. He was formerly the Group Medical Director, CV and Metabolic Disease in Global and Discovery Medicine at Bristol Myers Squibb and head of Therapeutic Angiogenesis research at Proctor & Gamble Pharmaceuticals. Prior to that, Dr. Peters was an Associate Professor of Medicine and Pharmacology in the Division of Cardiology at Duke University Medical Center. Dr. Peters received his M.D. from the University of Iowa and was a Research Fellow and Adjunct Professor at the University of California, San Francisco. Dr. Peters has published broadly in the areas of growth factor receptor signaling and vascular biology and has led several preclinical programs to clinical proof of concept in vascular and metabolic diseases.
MD - Chief Scientific Officer